rs1057519783
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
|
24736079 |
2014 |
rs1057519783
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Non-small-cell lung cancer (NSCLC) patients harboring ALK or ROS1 rearrangements invariably acquire resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs), most notably ALK G1202R and ROS1 G2032R.
|
30683630 |
2019 |
rs1057519783
|
|
|
0.040 |
GeneticVariation |
BEFREE |
These results demonstrated how the mutated residues tune the crizotinib response and may assist kinase inhibitor development especially for ALK G1202R, analogous to the ROS1 G2302R and MET G1163R mutations that are also resistant to crizotinib treatment in NSCLC.
|
31388026 |
2019 |
rs1057519783
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We also discovered four novel somatic ALK mutations in NSCLC (T1151R, R1192P, A1280V, and L1535Q) that confer primary resistance; all of them showed strong resistance to ALK inhibitors, as G1202R does.
|
28741662 |
2017 |
rs1057519698
|
|
|
0.030 |
GeneticVariation |
BEFREE |
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
|
25736571 |
2015 |
rs1057519698
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
|
25393796 |
2014 |
rs1057519698
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
|
27565911 |
2016 |
rs1057519784
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Alectinib is a new generation ALK inhibitor with activity against the gatekeeper L1196M mutation that showed remarkable activity in a phase I/II study with echinoderm microtubule associated protein-like 4 (EML4)--anaplastic lymphoma kinase (ALK) non-small cell lung cancer (NSCLC) patients.
|
24952482 |
2014 |
rs1057519784
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation.
|
29067524 |
2017 |
rs281864719
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Here, we identified a novel secondary acquired NSCLC ALK F1174V mutation by comprehensive next-generation sequencing in one ALK+ NSCLC patient who progressed on crizotinib after a prolonged partial response to crizotinib.
|
24736079 |
2014 |
rs281864719
|
|
|
0.020 |
GeneticVariation |
BEFREE |
F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular simulations.
|
28622610 |
2017 |
rs1057519781
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The clinical efficacy of alectinib against a NSCLC patient harboring ALK G1269A mutation was evaluated in the phase I part of the North American study.
|
26849637 |
2016 |
rs113994088
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified a novel acquired NSCLC ALK G1128A mutation in the ALK + NSCLC patient who progressed on crizotinib after a short partial response to the drug.
|
30089600 |
2018 |
rs113994091
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also discovered four novel somatic ALK mutations in NSCLC (T1151R, R1192P, A1280V, and L1535Q) that confer primary resistance; all of them showed strong resistance to ALK inhibitors, as G1202R does.
|
28741662 |
2017 |
rs550608288
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Low frequency KRAS active (G12R) and EGFR kinase domain mutations (G719A) were identified in one NSCLC patient.
|
24200637 |
2014 |
rs751306825
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A recent study reported the newest generation inhibitor resistant mutation L1198F led to the resensitization to crizotinib, which is the first Food and Drug Administration (FDA) approved drug for the treatment of ALK-positive NSCLC.
|
28245558 |
2017 |
rs863225283
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here we described the emergence of an ALK F1245C mutation in an advanced ALK+ NSCLC patient (EML4-ALK variant 3a/b) who developed slow disease progression after a durable response to crizotinib.
|
26775591 |
2016 |
rs958335893
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We present a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib.
|
26237499 |
2015 |